ザナミビル ザナミビル水和物 zanamivir
WordNet
- any compound that contains water of crystallization
- become hydrated and combine with water
- cause to be hydrated; add water or moisture to; "hydrate your skin"
- supply water or liquid to in order to maintain a healthy balance; "the bicyclists must be hydrated frequently"
- small tubular solitary freshwater hydrozoan polyp
- trouble that cannot be overcome by a single effort because of its many aspects or its persistent and pervasive quality; "we may be facing a hydra that defies any easy solution"
PrepTutorEJDIC
- 含水化合物,水化物 / 〈化合物〉‘を'水和させて水化物を作る
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.
- Mizuno T1, Mizuno S2, Kanda T1.
- PloS one.PLoS One.2014 Apr 3;9(4):e92601. doi: 10.1371/journal.pone.0092601. eCollection 2014.
- BACKGROUND: Evidence of the effectiveness of influenza vaccination in children and elderly adults is limited, although this population has the highest risk for influenza infection.MATERIALS AND METHODS: We enrolled 4443 participants, aged 3-97 years, who had influenza-kit-positive resultsduring seas
- PMID 24699254
- Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
- Nakano T1, Okumura A, Tanabe T, Niwa S, Fukushima M, Yonemochi R, Eda H, Tsutsumi H.
- Scandinavian journal of infectious diseases.Scand J Infect Dis.2013 Jun;45(6):469-77. doi: 10.3109/00365548.2012.763104. Epub 2013 Feb 4.
- BACKGROUND: Abnormal behavior and delirium are common in children with influenza. While abnormal behavior and delirium are considered to be associated with influenza encephalopathy, an increased risk of such neuropsychiatric symptoms in patients receiving neuraminidase inhibitor treatment is suspect
- PMID 23373850
- Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.
- Kashiwagi S1, Yoshida S, Yamaguchi H, Mitsui N, Tanigawa M, Shiosakai K, Yamanouchi N, Shiozawa T, Yamaguchi F.
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.J Infect Chemother.2013 Apr;19(2):223-32. doi: 10.1007/s10156-012-0481-9. Epub 2012 Oct 20.
- Laninamivir octanoate hydrate (laninamivir) is a long-acting neuraminidase inhibitor which requires only a single inhaled dose to fully treat infection by the influenza virus. In Japan, this drug was launched in October 2010 as a new treatment for the influenza virus. A postmarketing surveillance st
- PMID 23085742
Japanese Journal
- A Fatal Case of Acute Encephalopathy in a 8-year-old girl from a Pandemic of Influenza A( H1N1) in 2009
- George Imataka/Eisei Hoshiyama / Keiko Tsukada/ Kenji Miyamoto/Yoshiyuki Watabe/ Yuya Sato/ Osamu Arisaka
- Dokkyo journal of medical sciences 38(2), 161-164, 2011-07-25
- … The case pertains to an 8-year-old girl, who was diagnosed with influenza A on the previous day andwas prescribed zanamivir hydrate. …
- NAID 110008669251
- Influenza-associated Monophasic Neuromyelitis Optica
- Nakamura Yoshikazu,Ikeda Ken,Yoshii Yasuhiro,Ito Hirono,Hirayama Takehisa,Kawabe Kiyokazu,Kano Osamu,Iwasaki Yasuo
- Internal Medicine 50(15), 1605-1609, 2011
- … She was diagnosed as influenza A and was treated with zanamivir hydrate (10 mg/day, inhalation). …
- NAID 130000969357
- 診療と研究 パンデミックインフルエンザA(H1N1)2009流行期におけるザナミビルの効果を2008〜2009シーズンと比較して
Related Links
- Visit ChemicalBook To find more ZANAMIVIR HYDRATE(139110-80-8) information like chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight, physical properties,toxicity information ...
- ZANAMIVIR HYDRATE CAS # 139110-80-8 MF C12H20N4O7 MW 332.31 EC # Unknown HS CODE Standard Size SKU SIZE / UOM PRICE Purity Availability Qty / Add To Cart CA000308 Call for price Login for price 0.0000 ...
Related Pictures
★リンクテーブル★
[★]
- 英
- zanamivir
- 化
- ザナミビル水和物 zanamivir hydrate
- 商
- リレンザ Relenza
- 関
- 抗ウイルス薬、ウイルス、インフルエンザウイルス、オセルタミビル
作用機序
薬理作用
適応
処方
- インフルエンザ感染症の症状が出現したのち24-36時間以内に投与で、インフルエンザ感染症の症状を軽減できる。
注意
禁忌
副作用
[★]
- 関
- hydration、water supply
[★]
ヒドラ
- 関
- Hydra